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Objective: To investigate anti-infective treatments in HIV-infected surgical patients during the perioperative period.
Methods: A retrospective study of sepsis and surgical site infections (SSIs) was conducted in 266 HIV-infected
patients. The patients were divided into 3 groups based on CD4+ T cells counts in the preoperative period: group
A (0–199 cell/ul), group B (200–349 cell/ul) and group C ([greater than or equal to] 350 cell/ul). When the CD4
count was below 350 cells/uL, anti-retrovirus therapy was started. For patients whose preoperative CD4 counts
were [less than or equal to] 200 cells/uL, preoperative antibiotic medication was started.
Results: Patients in group A were more likely to get sepsis than patients in the other two groups (p0.01). Among
82 patients with clean wounds, only one patient got SSIs. All patients with dirty wounds had acquired SSIs after
surgery. There were only 6 patients dead at 30 days after surgery, a death rate of 2.3%. Sepsis appeared in 110
patients (41%).
Conclusions: Complete evaluation of surgical risk and suitable perioperative anti-infective treatment may lead to
better outcome for HIV-infected surgical patients.
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The patient who undergoes surgical treatment may ex-
perience postoperative infection. According to wound
class and immune status, the postoperative infection
rates are different. Based on the National Nosocomial
Infections Surveillance (NNIS) system, surgical site
infections (SSIs) are the third most frequently reported
nosocomial infection, and the most common on surgical
wards [1]. The Centers for Disease Control and Preven-
tion (CDC) estimates that 22% of all health-care-
associated infections are SSIs, with an increasing per-
centage over the last decade [1,2]. SSIs increase morbid-
ity as well as mortality, double the length of hospital
stay [3-6] and increase the cost of surgery two- to five-
fold [7].
The progressive failure of the immune system caused
by HIV can increase the possibility of developing post-
operative infection. In recent years, the number of HIV-* Correspondence: liubaochi2002@yahoo.com.cn
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reproduction in any medium, provided the orinfected patients is progressively increasing. The intro-
duction of antiretroviral therapy (ART) has significantly
improved the life expectancy of patients infected with
HIV and those diagnosed with AIDS [8-13]. The demand
for surgical treatment in HIV-infected patients is in-
creasing and so is the frequency of resultant surgical dis-
ease [14,15].
There are few reported data on the efficacy of anti-
infective treatment in HIV-infected patients during the
perioperative period. Since our institution is a designated
tertiary care university hospital for treatment of HIV-
infected patients we had the opportunity to investigate
the efficacy of anti-infective treatments in HIV-infected
patients during the perioperative period.Patients and methods
Definitions
We defined the wound class at the surgical site of infec-
tion (SSI) using the definitions provided by the Centers
for Disease Control and Prevention (CDC). An instance
of surgical site infection was defined as an infection oc-
curring within 30 days of the operative procedure, whenThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of patients
Variable No. Percent of total
study population









Liu et al. AIDS Research and Therapy 2012, 9:36 Page 2 of 5
http://www.aidsrestherapy.com/content/9/1/36the patient had one or more of the following: (1) organ-
isms isolated from an aseptically obtained culture of
fluid or tissue from the surgical incision; (2) purulent
drainage from the surgical incision; (3) at least one of
the following: pain or tenderness, localized swelling, red-
ness, or heat. SSIs were classified as being incisional,
deep incisional or organ/space. Surgical procedures were
classified as clean, contaminated or dirty. Sepsis was
defined as the infection in association with systemic in-
flammatory response syndrome.
Data collection
Clinical data of HIV-infected patients undergoing
surgery from January 2009 to December 2011 were
retrieved using our computerized patient record system.
Inclusion criteria: HIV-infected patients were identified
and diagnosed by local Centers for the Disease Preven-
tion and Control in different locations in China. All
selected patients had records that contained thorough
disease histories, including physical examinations, pre-
operative and postoperative routine examinations, and
immune function tests.
Patient group and study methods
We stratified and compared the incidence of SSIs and
sepsis according to both wound class and preoperative
CD4 counts with breakpoint values of 200 and 350 cell/
μL. Demographic and clinical information was entered
into a database that included: type of surgical procedure,
age, peripheral blood cell counts, plasma albumin, CD4
counts, and CD4/CD8 ratios.
Statistical analysis
Date were analyzed using SPSS 16.0 statistical software
(SPSS Inc., Chicago, IL). Results of all continuous data
are presented here as mean ± standard deviation. Con-
tinuous variables were compared by independent t-test.
Univariate analysis of the categorical outcome was car-
ried out using Chi-squared tests. P<0.05 indicates statis-
tical significance.
Results
Two hundred and sixty-six HIV-infected patients were
included in this study. Their mean (±SD) age was 42.3
(±13.1) years, and 237 (89.1%) were male. There were
six deaths in the study population, five of whom had
organ/space SSI and developed sepsis. The SSI cumula-
tive incidence rate was 46.6% (124 of 266). The inci-
dence of incisional SSI was 37.6%, deep incisional SSI
was 5.3%, and organ/space SSI was 3.8%. Baseline char-
acteristics of patients shown in (Table 1).
Univariate analysis revealed that the following vari-
ables were associated with the occurrence of sepsis:preoperative WBC, hemoglobin, CD4, CD8 and CD4/
CD8 (Table 2).
At multivariate analysis, only preoperative WBC,
hemoglobin and CD4 remained significantly (P<0.05)
associated with sepsis, (Table 3).
Comparisons of the incidence of sepsis according to
preoperative CD4 counts shown in Table 4.
Patients with lower preoperative CD4 counts undergo-
ing surgery were more likely to develop sepsis.Surgical
procedures were classified as clean (N = 82; 30.8%), con-
taminated (N = 171; 64.3%) and dirty (N = 13; 4.9%). The
incidence of SSI differed significantly depending on
wound class, and increased from 1.2% in patients with
clean wounds to 100% in patients with dirty wound
(Table 5).
Our data show that SSIs were frequent and differed
widely by wound class. Patients with SSIs were more
likely to develop postoperative sepsis than non-SSIs
patients (Table 6).
Discussion
Anti-infective treatment in the perioperative period
HIV mainly invades and destroys CD4 T lymphocytes,
causing CD4 counts to gradually decrease. In conse-
quence of their significantly impaired immune function
when the,CD4 count is below 350 cell/μL, HIV-infected
patients are likely to get opportunistic infections and
cancers and their mortality is then usually high [16]. At
this stage ART is used, and usually includes two kinds
of nucleosides and one kind of protease inhibitor.
Patients using ART who undergo surgery need to con-
tinue ART use during the perioperative period [17].
Even if patients are undergoing gastrointestinal surgery
and need to fast, they can take antiviral drugs. When a
patient's, CD4 count is below 200 cell/μL, there is an
additional high risk of acquiring fungal infections such as
Pneumocystis carinii pneumonia which bring a marked
increase in mortality [18,19]. Therefore SMZ and fluco-
nazole are conventionally added to ART during the peri-
operative period to prevent P. carinii pneumonia and
other fungal infections. If tuberculosis, cryptococcosis,
Table 2 Comparisons of age and clinical date between sepsis group and non-sepsis group
Parameters Sepsis group Non-sepsis group t P
Age(y) 41.8 ± 12.7 42.7 ± 13.8 −0.529 0.598
Viral load 105027.01 ± 2.58*105 46203.79 ± 1.02*105 1.071 0.26
WBC(x109/L)* 6.15 ± 3.317 5.23 ± 1.79 2.625 0.010
Hemoglobin (g/L)* 113.7 ± 24.9 130.1 ± 23.2 −5.349 0.000
Platelet (x109/L ) 213.4 ± 114.5 190.51 ± 75.19 1.821 0.070
CD4 (cell/ul)* 172.6 ± 163.4 324.01 ± 242.64 −5.349 0.000
CD8 (cell/ul)* 666.9 ± 485.4 798.43 ± 424.348 −2.132 0.034
CD4/CD8* 0.30 ± 0.25 0.4532 ± 0.3129 −3.836 0.000
* Statistical significance.
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surgery, anti-TB or antifungal treatments are clearly
required to control the disease. In summary, HIV
patients undergoing emergency surgery need prophylac-
tic anti-infective drugs based on doctor/clinical experi-
ence, and effective anti-infective treatments are to be
applied according to the results of resection of lesions
and blood culture [20,21].
Prophylactic antibiotics
To reduce the incidence of surgical site infection,
prophylactic antibiotics are generally used during the
perioperative period. Because of the weakened immune
function, HIV-infected patients are even more likely to
need prophylactic antibiotics [22]. However, there are no
reports specifically about how to use antibiotic in surgi-
cal patients who are HIV infected. We found that pre-
operative CD4 lymphocytes, WBC and hemoglobin are
independent risk factors for sepsis. CD4 counts cannot
be implied from white blood cell counts. Decline in CD4
T lymphocyte counts is often accompanied by decline in
hemoglobin. Our principle in using prophylactic antibio-
tics was to use those antibiotics which can cover the
most common infections according to surgical incision
site and type of surgery. We took into account the likeli-
hood of Gram-negative bacilli (enteric bacteria), gram-
positive cocci (Staphylococcus aureus) and anaerobic
bacteria, and chose between two kinds of antibiotic com-
binations. We usually selected first-generation cephalos-
porins on clean wound surgery. For nine patients whoTable 3 Independent risk factors for perioperative sepsis
estimated from multiple regression model
Risk factor OR 95%CI P value
Preoperative CD4* 6.069 1.001-1.010 0.014
Preoperative CD8 0.469 0.998-1.001 0.494
Preoperative CD4/CD8 0.2→ 1 0.027-8.425 0.616
Preoperative Hemoglobin * 4.302 1.001-1.036 0.038
Preoperative Albumin 0.12 0.962-1.028 0.729
Preoperative WBC* 5.814 0.719-0.996 0.016were undergoing excision of thyroid tumor or breast
tumor, we did not use any antibiotics and no SSI arose.
In all, 82 patients underwent clean wound surgery and
81 had healing wounds. In future we may try not using
any antibiotic for classIminor incisions. For giant splen-
ectomy with cirrhosis and for internal fixation of femoral
fractures, we still need prophylactic antibiotics, and they
should be used longer than for normal surgery. We gen-
erally use antibiotics until wound have healed. The first-
generation cephalosporins have a strong bactericidal ac-
tivity for Gram-positive S. aureus, but for Gram-positive
intestinal bacteria its bactericidal activity is less than
second- and third-generation cephalosporins (ceftriax-
one, etc.). Second-generation cephalosporins have
advantages in the prevention of wound infection for
class-IIincisions and gastrointestinal tract surgery, but
its bactericidal activity is less than third-generation
cephalosporins in the prevention of intra-abdominal in-
fection. Prophylactic antibiotics should also cover com-
mon anaerobic bacteria for lower gastrointestinal
surgery where there is significant pollution. Antibiotics
such as piperacillin, cefoxitin, cefotetan, etc., can cover
gram-negative enteric bacilli as well as anaerobic bac-
teria. Metronidazole and clindamycin should be included
when other antibiotics do not have activity against an-
aerobic bacteria.
Antibiotics for therapy
Therapeutic drugs should be used for intra or postopera-
tive infections. According to our statistical analysis of
the clinical data, the lower the preoperative CD4 counts,
the higher the incidence of sepsis. Our data also show
that SSIs were frequent and differed widely by woundTable 4 Incidence of postoperative sepsis according to
preoperative cd4 counts
Preoperative CD4 Sepsis Non-sepsis χ2 p
<200 cell/μl 68 (66.7%) 34 (33.3%) 41.404 <0.01*
200-349 cell/μl 18 (28.6%) 45 (71.4%)
≥350 cell/μl 13 (20.6%) 50 (79.4%)
* Statistical significance.
Table 5 Incidence of SSIs according to wound class
Wound class Non-SSIs SSIs χ2 p
clean 81 (98.8%) 1 (1.2%) 104.349 <0.001*
contaminated 61 (35.7%) 110 (64.3%)
dirty 0 13 (100%)
* Statistical significance.
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because our study included many anal warts excision
patients and these usually develop SSIs after surgery.
Clearly, we should maintain clean wounds for superficial
surgical site infections to reduce sepsis; our data show
that the incidence of sepsis in the SSIs group was signifi-
cantly higher than in the non-SSIs group. Therefore ef-
fective treatment should also be used for surgical site
infection. Effective anti-infection treatment involves a
multi-disciplinary knowledge for HIV-infected patients
who may have tuberculosis, fungal infections and surgi-
cal site infections.Surgical risk and prognosis
HIV-infected patients have a higher incidence of surgical
complication and mortality than normal patients.
Jeremiah L et al. [23] reported that the incidence of
postoperative infectious complications was 55% and the
30-day mortality rate after surgery was 30% for HIV-
infected patients. Our institution is a designated tertiary
care university hospital for treatment of HIV-infected
patients, so we have accumulated much perioperative
anti-infection treatment experience. The mortality of
HIV-infected patients undergoing abdominal surgery in
our hospital was 7.7% which is significantly lower than
previously reported data. Surgeons should pay attention
to occupational exposure and aseptic technique in order
to reduce SSIs and surgical trauma.Limitations of the study
One of the limitations of the study was possible informa-
tion biases due to the retrospective nature of the study
design. Another was that the study did not control for
possible confounders other than those investigated.
In conclusion, in order to reduce the incidence of in-
fection complications and mortality, surgeons should
combine multidisciplinary knowledge and carry out rea-
sonable anti-infection treatments.Table 6 Incidence of postoperative sepsis according to
SSIs
Sepsis Non-sepsis χ2 p
SSIs 63(50.8%) 61(49.2%) 8.559 0.003*
Non-SSIs 47(33.1%) 95(66.9%)
* Statistical significance.Ethical approval
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